Lisata Therapeutics, Inc. (LSTA) - 10-Q Summary
Business Context and Reporting Period
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company developing certepetide, a novel therapy designed to enhance the delivery of anti-cancer drugs to solid tumors via the CendR active transport mechanism. The company is currently conducting Phase 2 clinical trials for metastatic pancreatic ductal adenocarcinoma (mPDAC) and other solid tumors. This report covers the quarterly period ended September 30, 2025.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $70,000 | $0 |
| Net Loss | $(4.25) million | $(4.93) million | $(13.63) million | $(15.38) million |
| Operating Expenses | $(4.41) million | $(5.34) million | $(15.20) million | $(17.46) million |
| Cash & Equivalents (End of Period) | $19.0 million | $19.5 million | $19.0 million | $19.5 million |
| Working Capital | $17.0 million | $29.0 million | $17.0 million | $29.0 million |
| Loss Per Share (Diluted) | $(0.49) | $(0.59) | $(1.58) | $(1.85) |
Note: All figures in millions unless otherwise noted. The company has no debt obligations listed on the balance sheet.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 17.3% in Q3 2025 compared to Q3 2024, driven by lower spending on Chemistry, Manufacturing, and Controls (CMC) and reduced clinical department costs. YTD operating expenses decreased by 12.9%.
- Revenue Recognition: The company recognized $70,000 in revenue for the nine months ended September 30, 2025, related to an upfront license fee from a research collaboration. No revenue was recognized in the comparable 2024 period.
- Liquidity Position: Cash and cash equivalents increased slightly to $19.0 million from $16.2 million at year-end 2024, despite a net cash burn of $12.7 million from operations. This was offset by net sales of marketable securities ($15.1 million provided by investing activities).
- Investment Income: Investment income decreased significantly year-over-year due to lower interest rates and the liquidation of marketable securities. Net investment income was $183,000 in Q3 2025 compared to $451,000 in Q3 2024.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash resources are sufficient to fund operations for at least the next 12 months. However, the company anticipates needing additional financing by the end of 2026 to meet long-term needs.
- Operational Adjustments: To preserve capital, the company has delayed certain readiness activities for its planned Phase 3 study in mPDAC, specifically those related to CMC. Ongoing trials continue as planned.
- Clinical Progress: Preliminary data from the ASCEND Phase 2b trial (Cohort B) showed clinically meaningful improvements in Progression-Free Survival (PFS) and Objective Response Rate (ORR) for patients treated with certepetide plus standard-of-care chemotherapy compared to placebo. Final data is expected in Q1 2026.
- Recent Agreements:
- Kuva Labs: Entered an exclusive license agreement in November 2024 for certepetide use with NanoMark imaging technology (recognized $1.0M revenue).
- Catalent: Entered a non-exclusive license agreement in October 2025 (subsequent event) to use certepetide as an ADC payload, with potential milestones up to $10.5 million.
- Risks: Key risks include the ability to secure additional capital, the success of clinical trials, regulatory approvals, and the potential dilution from future equity issuances. The company is subject to "Baby Shelf Limitations" on its At-The-Market (ATM) offering due to its public float size.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $19.0 million cash balance against the projected burn rate, considering the delay in Phase 3 CMC activities.
- ATM Capacity: Review the remaining capacity under the "Baby Shelf Limitation" (currently capped at one-third of public float, approx. $9.86 million) for near-term capital raising.
- Clinical Data: Monitor the release of final ASCEND trial data in Q1 2026 to validate the preliminary positive signals in PFS and ORR.
- Revenue Sustainability: Assess the likelihood of future milestone payments from the Qilu Pharmaceutical and Kuva Labs agreements, noting the $96M and $1.5M potential development milestones respectively.
- Legal Contingencies: Confirm the status of the settled litigation with Lingmed Limited and any ongoing obligations regarding future milestone sharing (5.0% of Qilu milestones).